IDEXX Laboratories Inc (IDXX)vsPfizer Inc (PFE)
IDXX
IDEXX Laboratories Inc
$575.72
+0.97%
HEALTHCARE · Cap: $45.53B
PFE
Pfizer Inc
$27.28
+1.19%
HEALTHCARE · Cap: $153.36B
Smart Verdict
WallStSmart Research — data-driven comparison
Pfizer Inc generates 1354% more annual revenue ($62.58B vs $4.30B). IDXX leads profitability with a 24.6% profit margin vs 12.4%. IDXX appears more attractively valued with a PEG of 3.97. IDXX earns a higher WallStSmart Score of 61/100 (C+).
IDXX
Buy61
out of 100
Grade: C+
PFE
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-40.2%
Fair Value
$462.85
Current Price
$575.72
$112.87 premium
Margin of Safety
-194.9%
Fair Value
$9.25
Current Price
$27.28
$18.03 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 66 in profit
Keeps 25 of every $100 in revenue as profit
Strong operational efficiency at 29.8%
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 23.9%
Generating 4.5B in free cash flow
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Trading at 28.6x book value
Weak financial health signals
Expensive relative to growth rate
Revenue declined 1.2%
Earnings declined 21.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : IDXX
The strongest argument for IDXX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 24.6% and operating margin at 29.8%. Revenue growth of 14.3% demonstrates continued momentum.
Bull Case : PFE
The strongest argument for PFE centers on Market Cap, Price/Book, Operating Margin.
Bear Case : IDXX
The primary concerns for IDXX are PEG Ratio, P/E Ratio, Price/Book. A P/E of 43.7x leaves little room for execution misses.
Bear Case : PFE
The primary concerns for PFE are Piotroski F-Score, PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
IDXX profiles as a mature stock while PFE is a declining play — different risk/reward profiles.
IDXX carries more volatility with a beta of 1.70 — expect wider price swings.
IDXX is growing revenue faster at 14.3% — sustainability is the question.
PFE generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
IDXX scores higher overall (61/100 vs 49/100), backed by strong 24.6% margins and 14.3% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
IDEXX Laboratories Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.
Pfizer Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?